

**REMARKS**

In the Office Action mailed October 10, 2006, the claims were divided into nine groups:

Group I - Claims 1-10, 25-37, 50-55, 82 and 83, drawn to a method for using high affinity TCRs to identify ligands and a method of binding a high affinity TCR to a cell carrying a selected peptide/MHC ligand;

Group II - Claims 11, 38-43 and 80-81, drawn to a method for blocking autoimmune destruction of cells and a pharmaceutical composition comprising a high affinity TCR;

Group III - Claims 12, 44-49, 70-71, 74, 75 and 80-81, drawn to a method for using high affinity TCRs coupled to a therapeutic compound to treat cancer or kill an undesirable cell and a pharmaceutical composition comprising a high affinity TCR;

Group IV - Claims 13-14, 72-72 and 80-81, drawn to a method for using high affinity TCRs coupled to a toxic compound to kill pathogen infected cells and a pharmaceutical composition comprising a high affinity TCR;

Group V - Claims 15-18, drawn to soluble TCRs;

Group VI - Claim 19, drawn to a DNA library comprising DNAs encoding high affinity TCRs;

Group VII - Claim 20, drawn to a library of TCR proteins displayed on yeast cells;

Group VIII - Claims 21-24, 56-63, 64-69 and 79, drawn to a method for cloning a high affinity TCR; and,


Group IX - Claims 76-78, drawn to a method for treating disease in a patient comprising the steps of: removing wild-type T cells from the patient; transforming the T cells with the vector that expresses a high affinity TCR mutant, to express the high affinity TCR in the T cells; returning the transformed T cells to the patient; wherein the transformed T cells are activated to a greater extent than the wild type T cells of the patient.

In response, applicant elects Group I, with traverse. All claims in Groups I - IX recite high affinity TCRs and as such, a search for this concept is believed to be required for all groups. It is believed examination of all groups together would not be burdensome.

### CONCLUSION

This response is accompanied by a Petition for Extension of Time (two months) and an authorization to charge the fee due (believed to be \$450.00 for a two month extension of time) to Deposit Account No. 07-1969. If this is incorrect however, please charge any fees required, including any extensions of time required, to Deposit Account No.07-1969.

Respectfully submitted,



Susan K. Doughty  
Reg. No. 43,595

**GREENLEE, WINNER AND SULLIVAN, P.C.**  
4875 Pearl East Circle, Suite 200  
Boulder, CO 80301  
Telephone: (303) 499-8080  
Facsimile: (303) 499-8089  
E-mail: [winner@greenwin.com](mailto:winner@greenwin.com)  
Attorney Docket No. 89-99A  
January 10, 2007